# Ralinepag PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ralinepag

> The PDUFA target action date for ralinepag, sponsored by UNITED THERAPEUTICS Corp (UTHR), is June 24, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ralinepag PDUFA date?

The PDUFA target action date for ralinepag, sponsored by UNITED THERAPEUTICS Corp (UTHR), is June 24, 2027. Status: scheduled. SEC Form 10-Q: "In August 2026, we were notified that the FDA had accepted our NDA and established a user fee goal date of June 24, 2027." Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/ralinepag)

Source: SEC Form 10-Q, accession 0001082554-26-000035, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/ralinepag#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ralinepag |
| Codes | MNKD-1501, APD811 |
| Sponsor | UNITED THERAPEUTICS Corp (UTHR) https://sec-api.dev/companies/uthr/catalysts |
| Indications | PAH |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 31, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03626688 (A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-31 (ACTUAL); Lead Sponsor United Therapeutics." https://clinicaltrials.gov/study/NCT03626688

### Jun 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-08-05, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001082554-26-000035): "In June 2026, we submitted an NDA to the FDA seeking approval to market ralinepag extended-release tablets for PAH." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm
- SEC Form 10-Q (accession 0001082554-26-000027): "In June 2026, we submitted an NDA to the FDA seeking approval to market ralinepag extended-release tablets for PAH." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000027/uthr-20260630.htm

### Aug 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001082554-26-000035): "In August 2026, we were notified that the FDA had accepted our NDA and established a user fee goal date of June 24, 2027." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics." https://clinicaltrials.gov/study/NCT03683186

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics." https://clinicaltrials.gov/study/NCT03683186

### June 24, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001082554-26-000035): "There can be no assurance that ScinoPharm's facility will be determined compliant, or that any required subsequent FDA inspections can be completed before the anticipated June 2027 action date for our ralinepag NDA." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm
- SEC Form 10-Q (accession 0001082554-26-000035): "However, qualifying any new manufacturing source is a lengthy and uncertain process that likely will not be completed in advance of the anticipated June 2027 action date for our ralinepag NDA." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm
- SEC Form 10-Q (accession 0001082554-26-000035): "In August 2026, we were notified that the FDA had accepted our NDA and established a user fee goal date of June 24, 2027." https://www.sec.gov/Archives/edgar/data/1082554/000108255426000035/uthr-20260930.htm

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ralinepag.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ralinepag PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ralinepag

```bibtex
@misc{secapidev_pdufa_ralinepag_20261116,
  title        = {Ralinepag PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ralinepag}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ralinepag_20261116","title":"Ralinepag PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ralinepag","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
